Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Zydus unveils its ‘innovation and care’ centric corporate brand identity
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Adds five years of market exclusivity on approval
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Subscribe To Our Newsletter & Stay Updated
